Bolt Biotherapeutics, Inc.
BOLT Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$6.27
KIRA · Stoqly’s AI analyst, in plain words
- Bolt Biotherapeutics, Inc. had $7.7M of revenue in fiscal 2025, up 0.1% on the year before. Over five years, revenue changed +101.6% a year on average.
- Its operating margin was −469.3%, up 480.6 pts: of every 100 in sales, about −469 is left after running the business.
- Bolt Biotherapeutics, Inc. lost $33.4M in fiscal 2025.
- Free cash flow was −$39.9M in fiscal 2025, −518.8% of revenue.
Market cap
$10.6M
P/E
—
Revenue
$7.7M
Net income
−$33.4M
Free cash flow
−$39.9M
Operating margin
−469.3%
Bolt Biotherapeutics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+0.1%
Only a little. Sales grew 0.1% last year.
Does it make a profit?
−433.7%
No. It lost money last year.
Does profit turn into cash?
−518.8%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 7
Mixed. It passes 4 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Bolt Biotherapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 12, 2026
- Legal name
- Bolt Biotherapeutics, Inc.
- CIK
- 0001641281
Bolt Biotherapeutics, Inc. · BOLT
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $1.3M | $5.7M | $7.9M | $7.7M | $7.7M |
| Revenue growth | 445.5% | 354.7% | 37.5% | −2.4% | 0.1% |
| Operating margin | −7,364.1% | −1,576.6% | −967.4% | −949.9% | −469.3% |
| Net income | −$98.6M | −$88.1M | −$69.2M | −$63.1M | −$33.4M |
| Net margin | −7,824.7% | −1,537.8% | −878.6% | −820.8% | −433.7% |
| Diluted EPS | −$2.97 | −$2.36 | −$1.83 | −$33.06 | −$17.85 |
| Cash | |||||
| Cash from operations | −$57.1M | −$76.5M | −$69.5M | −$61.3M | −$39.9M |
| Capital expenditure | $2.3M | $2.0M | $0.2M | $0.0M | $0.1M |
| Free cash flow | −$59.4M | −$78.5M | −$69.7M | −$61.3M | −$39.9M |
| FCF margin | −4,714.6% | −1,369.5% | −885.4% | −797.5% | −518.8% |
| Share count change | 1,479.1% | 12.5% | 1.2% | −95.0% | −2.1% |
| Debt and strength | |||||
| Cash and short-term investments | $186M | $169M | $102M | $47.3M | $27.5M |
| Shareholders' equity | $250M | $172M | $113M | $57.2M | $26.5M |
| Current ratio | 8.9x | 7.5x | 5.2x | 3.2x | 3.6x |
| Returns and quality | |||||
| Return on equity | −135.8% | −41.8% | −48.7% | −74.3% | −79.7% |
| Return on tangible equity | −39.4% | −51.4% | −61.4% | −110.4% | −125.9% |
| Piotroski F-score | 3 | 2 | 1 | 3 | 4 |
| Altman Z'' | 3.9 | 0.6 | −4.6 | −15.2 | −27.3 |
Insiders bought, 12 months
$0.0M
2 insiders
Insiders sold, 12 months
$0.1M
3 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Bolt Biotherapeutics, Inc. · BOLT
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $6.27 a share, the company is worth $10.6M.
Source: SEC EDGAR XBRL filings (CIK 0001641281). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.